A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
M.D. Anderson Cancer Center
Inspirna, Inc.
EpicentRx, Inc.
Dana-Farber Cancer Institute
AbbVie
Amgen
University of California, San Francisco